查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018835

人类免疫力缺乏病毒（HIV）治疗市场：依药物类别、治疗方法、治疗阶段、给药途径、病患类型及通路划分－2026-2032年全球市场预测

Human Immunodeficiency Virus Therapeutics Market by Drug Class, Regimen Type, Therapy Line, Mode Of Administration, Patient Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人类免疫力缺乏病毒 (HIV) 治疗市场价值将达到 212.3 亿美元，到 2026 年将成长到 222.3 亿美元，到 2032 年将达到 293.2 亿美元，复合年增长率为 4.71%。

主要市场统计数据
基准年 2025 212.3亿美元
预计年份：2026年 222.3亿美元
预测年份 2032 293.2亿美元
复合年增长率 (%) 4.71%

引言部分阐述了塑造现代 HIV 治疗策略的临床进展、政策趋势和相关人员的需求。

在不断发展的爱滋病治疗领域，亟需一个入门框架，将近期临床进展、监管里程碑和商业性发展置于一个连贯的策略叙事框架内。本入门指南整合了从联合治疗免疫力缺乏疗法到现代重点领域（例如长效製剂、简化治疗方法和差异化护理路径）的科学发展轨迹，同时也探讨了扩大公平获取途径和降低发病率等仍然至关重要的公共卫生抗逆转录病毒。

本文探讨了由科学创新、监管变革以及患者和支付方期望的演变所推动的爱滋病治疗领域的主要变革性变化。

在科学突破、监管进步和患者期望不断变化等因素的推动下，爱滋病治疗领域正经历着一场变革性的转变，这些因素共同重塑了标准治疗方案和商业性机会。整合酶抑制剂和长效注射剂等创新疗法透过提高疗效、耐受性和依从性，正在改变治疗模式，从而鼓励医生和患者优先选择治疗方法。

本分析探讨了 2025 年美国关税措施将如何重塑整个 HIV 治疗生态系统的供应链、筹资策略和製造决策。

美国2025年实施的关税和贸易措施对爱滋病治疗药物的整个价值链产生了复杂的影响，波及筹资策略、製造地选择以及跨境供应的可靠性。製造商和经销商面临利润率和物流成本结构的更大压力，促使许多企业重新评估筹资策略，并探索近岸外包和双重采购机制，以降低关税变化带来的风险。因此，采购负责人和医疗系统在合约谈判中面临更大的复杂性，必须考虑到前置作业时间带来的不确定额外成本和更长的交货週期。

整合药物类别、给药方法、治疗线、给药途径、患者类型和分销管道等关键细分洞察，以进行策略性澄清。

精细化的细分观点能够清楚地展现临床、商业和营运重点的交会点，为跨产品系列和通路策略的策略决策提供系统性的基础。按药物类别划分，涵盖了进入抑制剂、整合酶链转移抑制剂、非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂。进入抑制剂以恩夫韦地和马拉维罗为例进行分析，而整合酶抑制剂则以比克替拉韦、多替拉韦、埃尔维格拉韦和拉替拉韦为例进行分析。透过依非韦伦、依曲韦林、奈韦拉平、利匹韦林检验非核苷类逆转录酶抑制剂，透过阿巴卡韦、恩曲他滨、拉米夫定、替诺福韦、齐多夫定来分析核苷类逆转录酶抑制剂，透过阿扎那韦、达芦那韦、福沙那韦、洛那韦抑制剂、洛那韦。

美洲、欧洲、中东和非洲以及亚太地区的主要区域趋势正在塑造准入途径、法规和商业化策略。

区域趋势对爱滋病治疗药物的临床应用、取得途径和商业策略有着显着影响，每个地区在监管、支付者和供应链方面都有其独特的考量。在美洲，成熟的法规结构、完善的治疗指南以及与集中支付方强大的议价能力，推动了对差异化治疗方法和基于疗效的合约的需求。同时，供应链的复杂性使得强大的经销伙伴和病患支援计画至关重要。

这是一份公司层面的策略洞察报告，详细介绍了原厂药生产商、生物技术公司、非专利药生产商和生产合作伙伴如何塑造 HIV 治疗市场的竞争格局和市场准入。

主要企业和策略性参与企业透过对研发管线的投资、伙伴关係模式和生产规模，在塑造爱滋病治疗生态系统中扮演不同的角色。原厂药厂持续投资于下一代分子、长效平台和新型给药系统，利用临床差异化优势力求占据高端市场地位，同时制定生命週期策略以应对非专利的市场份额侵蚀。同时，生技公司正透过敏捷地开发First-in-Class的作用机制和生物製药方法来推动创新，并经常与主要参与者合作，以利用其研发专长和商业性影响力。

为行业领导者提供切实可行的建议，以促进治疗方法创新与具有韧性的供应链、支付方参与和以患者为中心的服务模式的融合。

产业领导者应优先考虑一系列切实可行的策略，将科学创新与供应链韧性、支付方合作以及以患者为中心的服务模式相结合，从而在改善公共卫生结果的同时创造价值。首先，企业应透过建立多元化的采购管道、认证替代製造商以及采取紧急库存管理措施来增强供应链多元化，以应对贸易和物流中断。其次，在投资研发长效製剂和简化给药方法的同时，应进行有针对性的证据研究，证明提高用药依从性和提升医疗系统效率的益处，从而促进支付方接受并将其纳入处方集。

采用综合调查方法，结合一手访谈、二手文献回顾和检验，以检验见解和策略意义。

本分析的调查方法结合了严谨的一手和二手研究手段，以确保研究结果的可靠性、有效性和可重复性。一手研究包括与各类利益相关者进行结构化访谈和定性讨论，这些利益相关者包括临床医生、采购专业人员、支付方、关键意见领袖（KOL）和行业高管，旨在收集他们对临床实践、报销趋势和运营限制的真实观点。这些对话旨在揭示影响治疗选择、获取医疗服务的障碍以及所有相关人员策略重点的因素。

总结整合工作，强调临床创新、支付方合作和弹性运作结构的策略协调，以改善 HIV 治疗的可近性和治疗效果。

总之，现代爱滋病治疗格局的特点是临床创新显着、监管机构和支付方的期望不断变化，以及对供应链韧性和公平获取的日益重视。整合酵素抑制剂和长效药物体现了治疗进展如何改善患者的用药依从性和体验，而商业性现实则凸显了製定一项平衡创新、可负担性和可靠供应的综合策略的必要性。因此，相关人员必须采取综合方法，将临床差异化与实际营运效率结合。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：免疫力缺乏病毒（HIV）治疗市场：依药物类别划分

  • 入侵抑制剂
    • 恩夫维尔奇德
    • 马拉威罗克
  • 整合酶/链转移抑制剂
    • 比克替拉韦
    • 多替拉韦
    • 埃尔维特格拉维尔
    • 拉特格拉维尔
  • 非核苷类逆转录酶抑制剂
    • 依非韦伦
    • 依福西林
    • 奈韦拉平
    • 利匹韦林
  • 核苷类逆转录酶抑制剂
    • 阿巴卡韦
    • 恩曲他滨
    • 拉米夫定
    • 替诺福韦
    • 齐多夫定
  • 蛋白酶抑制剂
    • 阿扎那韦
    • 达芦那韦
    • 福斯帕奈韦
    • 洛匹那韦

第九章：人类免疫力缺乏病毒（HIV）治疗市场：依治疗方法

  • 组合方案
  • 单药治疗方案

第十章：免疫力缺乏病毒（HIV）治疗市场：依治疗阶段划分

  • 一线治疗
  • 补救性治疗
  • 二线治疗

第十一章：免疫力缺乏病毒（HIV）治疗市场：依给药途径划分

  • 注射药物
  • 口服

第十二章：免疫力缺乏病毒（HIV）治疗市场：依患者类型划分

  • 成人
  • 儿童

第十三章：人类免疫力缺乏病毒（HIV）治疗药物市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章：免疫力缺乏病毒（HIV）治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：免疫力缺乏病毒（HIV）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 人类免疫力缺乏病毒（HIV）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 美国：人类免疫力缺乏病毒（HIV）治疗市场

第十八章 中国：人类免疫力缺乏病毒（HIV）治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Aspen Pharmacare Holdings Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hetero Labs Limited
  • Janssen Pharmaceutica NV
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
  • Zydus Lifesciences Limited
Product Code: MRR-ED54C46E8CF6

The Human Immunodeficiency Virus Therapeutics Market was valued at USD 21.23 billion in 2025 and is projected to grow to USD 22.23 billion in 2026, with a CAGR of 4.71%, reaching USD 29.32 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 21.23 billion
Estimated Year [2026] USD 22.23 billion
Forecast Year [2032] USD 29.32 billion
CAGR (%) 4.71%

Introductory framing that contextualizes clinical advances, policy developments, and stakeholder imperatives shaping contemporary HIV therapeutic strategies

The evolving landscape of human immunodeficiency virus therapeutics demands an introductory framework that situates recent clinical advances, regulatory milestones, and commercial dynamics within a coherent strategic narrative. This introduction synthesizes the scientific trajectory from combination antiretroviral therapy to contemporary priorities such as long-acting formulations, simplified regimens, and differentiated care pathways, while also acknowledging the persistent public health imperative to expand equitable access and reduce morbidity.

Moreover, the introduction clarifies stakeholder perspectives across clinicians, payers, manufacturers, and patient advocates, highlighting how clinical efficacy, tolerability, and real-world adherence shape treatment selection and commercialization. It delineates the interplay between therapeutic innovation and health system capacity, emphasizing how shifts in administration modality and regimen complexity have direct implications for supply chains and distribution strategies. Consequently, this framing sets expectations for deeper sections that analyze regulatory trends, competitive dynamics, and market segmentation, thereby equipping decision-makers with the context needed to prioritize investment, policy engagement, and strategic partnerships.

Examining the major transformative shifts in HIV therapeutics driven by scientific innovation, regulatory change, and evolving patient and payer expectations

The therapeutic landscape for HIV has undergone transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing patient expectations, which together are redefining standard-of-care and commercial opportunity. Innovations such as integrase inhibitors and long-acting injectable formulations have altered treatment paradigms by improving potency, tolerability, and adherence profiles, thereby encouraging prescribers and patients to prioritize regimens that reduce pill burden and support sustained viral suppression.

Concurrently, regulatory pathways have adapted to accommodate faster approvals for formulations that demonstrate meaningful improvements in adherence and quality of life, while payers and procurement agencies are increasingly emphasizing total cost of care and outcomes-based contracting. Moreover, the expanded focus on differentiated care models and decentralized delivery is reshaping distribution channels, as community-led programs and online pharmacies amplify reach. As a result, pharmaceutical companies must balance innovation with affordability and supply reliability, integrating patient-centered clinical development with pragmatic commercialization strategies to capture value while advancing public health goals.

Analyzing how the 2025 United States tariff measures reshaped supply chains, procurement strategies, and manufacturing decisions across the HIV therapeutics ecosystem

The imposition of tariffs and trade measures by the United States in 2025 introduced a complex set of effects across the HIV therapeutic value chain, influencing procurement strategies, manufacturing location decisions, and cross-border supply reliability. Manufacturers and distributors experienced increased pressure on margins and logistical cost structures, prompting many to reassess sourcing strategies and to explore nearshoring or dual-sourcing arrangements to mitigate exposure to tariff volatility. Consequently, procurement officers and health systems faced heightened complexity when negotiating contracts that now needed to account for contingent tariff-related surcharges and longer lead times.

Moreover, tariffs altered the calculus for investment in domestic production capacity and strategic stockpiling, accelerating conversations around resilience and self-sufficiency for critical antiretrovirals and key active pharmaceutical ingredients. In response, several stakeholders intensified collaboration with contract manufacturers and exporters in tariff-exempt jurisdictions, while others accelerated investments in regulatory harmonization to streamline cross-border distribution. These adaptive measures, taken together, underscore the strategic necessity of supply chain agility and informed policy engagement to preserve patient access and maintain program continuity amid trade-induced disruption.

Critical segmentation insights that integrate drug class, regimen type, therapy line, administration mode, patient type, and distribution channel for strategic clarity

A granular segmentation lens clarifies where clinical, commercial, and operational priorities converge, providing a structured basis for strategic decision-making across product portfolios and channel strategies. Based on drug class, analysis spans Entry Inhibitors, Integrase Strand Transfer Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors, with Entry Inhibitors examined through Enfuvirtide and Maraviroc; Integrase inhibitors covered via Bictegravir, Dolutegravir, Elvitegravir, and Raltegravir; Non-Nucleoside reverse transcriptase inhibitors considered through Efavirenz, Etravirine, Nevirapine, and Rilpivirine; Nucleoside reverse transcriptase inhibitors analyzed including Abacavir, Emtricitabine, Lamivudine, Tenofovir, and Zidovudine; and Protease Inhibitors evaluated through Atazanavir, Darunavir, Fosamprenavir, and Lopinavir.

Based on regimen type, the landscape distinguishes between Multi Tablet Regimen and Single Tablet Regimen, recognizing that simplification of dosing remains a central driver of adherence and therapeutic persistence. Based on therapy line, segmentation includes First Line, Salvage Therapy, and Second Line, which informs development priorities for agents intended for treatment-experienced populations or for use where resistance patterns constrain options. Based on mode of administration, the analysis contrasts Injectable and Oral modalities, reflecting the commercial and operational ramifications of long-acting injectables versus daily oral therapies. Based on patient type, differentiation between Adult and Pediatric populations highlights formulation needs, palatability, and dosing considerations that influence pediatric program design. Finally, based on distribution channel, the framework examines Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy dynamics, recognizing that channel-specific procurement, reimbursement, and adherence support models materially affect uptake and access.

Key regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access pathways, regulation, and commercialization strategies

Regional dynamics materially influence clinical adoption, access pathways, and commercial strategies for HIV therapeutics, with each geography presenting distinct regulatory, payer, and delivery considerations. In the Americas, mature regulatory frameworks, established treatment guidelines, and concentrated payer negotiation leverage drive demand for differentiated regimens and outcomes-based contracting, while supply chain complexity necessitates robust distribution partnerships and patient support programs.

Across Europe, Middle East & Africa, heterogeneity in regulatory capacity, procurement models, and health system financing shapes varied adoption patterns; high-income markets prioritize innovation and formulary placement, whereas middle- and low-income settings emphasize affordability, generic competition, and procurement through pooled purchasing mechanisms. In Asia-Pacific, a mix of large domestic manufacturers, progressive regulatory reform in certain jurisdictions, and rapidly evolving private and public payer arrangements create opportunities for localized manufacturing, tiered pricing strategies, and digital health-enabled adherence interventions. Taken together, these regional distinctions underscore the need for tailored commercialization and access strategies that reflect regulatory timelines, procurement structures, and patient population characteristics.

Strategic company-level insights detailing how originators, biotech innovators, generics, and manufacturing partners shape competition and access in HIV therapeutics

Leading companies and strategic entrants each play distinct roles in shaping the HIV therapeutics ecosystem through pipeline investment, partnership models, and manufacturing scale. Originator pharmaceutical firms continue to invest in next-generation molecules, long-acting platforms, and novel delivery systems, leveraging clinical differentiation to pursue premium placements while managing lifecycle strategies against generic erosion. At the same time, biotechnology firms drive innovation with nimble development of first-in-class mechanisms and biologic approaches, frequently collaborating with larger partners to access development expertise and commercial reach.

Generic manufacturers and contract development and manufacturing organizations serve as critical pillars for affordability and supply resilience, particularly in regions where price sensitivity and centralized procurement dominate. Strategic partnerships, licensing agreements, and targeted acquisitions have become common tactics for companies seeking to quickly expand therapeutic breadth or to secure manufacturing capacity. In parallel, technology and digital health companies are increasingly adjacent players, offering adherence support, remote monitoring, and patient engagement solutions that enhance the real-world effectiveness of therapeutics. Together, these actors create an ecosystem where commercial success depends on scientific differentiation, strategic alliances, and the ability to operationalize distribution and patient support at scale.

Practical and actionable recommendations for industry leaders to align therapeutic innovation with resilient supply chains, payer engagement, and patient-centered delivery

Industry leaders should prioritize a suite of actionable strategies that align scientific innovation with supply resilience, payer engagement, and patient-centered delivery models to capture value while improving public health outcomes. First, firms ought to strengthen supply chain diversification by establishing multiple sourcing lanes, qualifying alternative manufacturers, and incorporating contingency inventory practices to guard against trade and logistics disruptions. Second, investment in long-acting formulations and simplified regimens should be paired with targeted evidence generation that demonstrates adherence benefits and health system efficiencies, thereby easing payer acceptance and formulary uptake.

Furthermore, organizations need to actively engage payers and procurement bodies early in development to design value propositions that speak to total cost of care, adherence outcomes, and real-world effectiveness. Concurrently, advancing pediatric-friendly formulations and pragmatic administration models will address persistent access gaps. Companies should also leverage partnerships for local manufacturing or technology transfer where appropriate, enabling tiered pricing and faster market entry. Finally, integrating digital adherence tools and patient support programs into commercialization plans will strengthen therapy persistence and outcomes. These recommendations collectively offer a roadmap for aligning innovation with pragmatic execution across clinical, regulatory, and commercial domains.

Comprehensive research methodology that integrates primary interviews, secondary literature review, and triangulation to validate insights and strategic implications

The research methodology underpinning this analysis combines rigorous primary and secondary approaches to ensure reliability, relevance, and reproducibility of insights. Primary research involved structured interviews and qualitative discussions with a cross-section of clinicians, procurement specialists, payers, key opinion leaders, and industry executives, enabling the capture of real-world perspectives on clinical practice, reimbursement dynamics, and operational constraints. These conversations were designed to surface drivers of treatment choice, barriers to access, and strategic priorities across stakeholder groups.

Secondary research complemented primary inputs through systematic review of peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to validate clinical and regulatory trends. Data triangulation techniques were applied to reconcile divergent sources and to strengthen confidence in thematic conclusions. Analytical rigor was further enhanced via scenario analysis and sensitivity checks to assess the robustness of strategic implications under varying assumptions. Ethical considerations, including the protection of participant confidentiality and avoidance of commercial bias, were integral to the research process, and limitations related to regional data granularity and rapidly evolving clinical evidence were transparently acknowledged.

Conclusive synthesis emphasizing strategic alignment of clinical innovation, payer engagement, and resilient operations to advance HIV therapeutic access and outcomes

In conclusion, the contemporary HIV therapeutics environment is characterized by meaningful clinical innovation, shifting regulatory and payer expectations, and a heightened focus on supply chain resilience and equitable access. Integrase inhibitors and long-acting modalities exemplify how therapeutic advances can translate into improved adherence and patient experience, while the commercial reality underscores the need for holistic strategies that reconcile innovation with affordability and distribution reliability. Consequently, stakeholders must adopt integrated approaches that bridge clinical differentiation with pragmatic operational execution.

Looking ahead, organizations that successfully align robust evidence generation, proactive payer engagement, and diversified manufacturing and distribution capabilities will be best positioned to deliver both commercial value and public health impact. Continued collaboration across industry, payers, providers, and community organizations will remain essential to translate therapeutic advances into durable improvements in treatment outcomes and access. Ultimately, strategic agility, evidence-based value propositions, and patient-centered delivery models will determine which programs attain sustainable success in this dynamic therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Immunodeficiency Virus Therapeutics Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Abacavir
    • 8.4.2. Emtricitabine
    • 8.4.3. Lamivudine
    • 8.4.4. Tenofovir
    • 8.4.5. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. Human Immunodeficiency Virus Therapeutics Market, by Regimen Type

  • 9.1. Multi Tablet Regimen
  • 9.2. Single Tablet Regimen

10. Human Immunodeficiency Virus Therapeutics Market, by Therapy Line

  • 10.1. First Line
  • 10.2. Salvage Therapy
  • 10.3. Second Line

11. Human Immunodeficiency Virus Therapeutics Market, by Mode Of Administration

  • 11.1. Injectable
  • 11.2. Oral

12. Human Immunodeficiency Virus Therapeutics Market, by Patient Type

  • 12.1. Adult
  • 12.2. Pediatric

13. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Human Immunodeficiency Virus Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Human Immunodeficiency Virus Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Human Immunodeficiency Virus Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Human Immunodeficiency Virus Therapeutics Market

18. China Human Immunodeficiency Virus Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Aspen Pharmacare Holdings Limited
  • 19.7. Aurobindo Pharma Limited
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Cipla Limited
  • 19.11. Genentech, Inc.
  • 19.12. Gilead Sciences, Inc.
  • 19.13. GlaxoSmithKline plc
  • 19.14. Hetero Labs Limited
  • 19.15. Janssen Pharmaceutica NV
  • 19.16. Merck & Co., Inc.
  • 19.17. Pfizer Inc.
  • 19.18. Shionogi & Co., Ltd.
  • 19.19. Sun Pharmaceutical Industries Ltd.
  • 19.20. Teva Pharmaceutical Industries Ltd.
  • 19.21. Viatris Inc.
  • 19.22. ViiV Healthcare Limited
  • 19.23. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ABACAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MULTI TABLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SINGLE TABLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SALVAGE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARK